Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Free Cash Flow (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Free Cash Flow for 3 consecutive years, with -$30.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 31.13% to -$30.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$129.8 million through Dec 2025, up 34.1% year-over-year, with the annual reading at -$129.8 million for FY2025, 34.1% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$30.1 million at Inhibrx Biosciences, up from -$33.8 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$30.0 million in Q2 2025, with the low at -$63.4 million in Q1 2024.
  • Average Free Cash Flow over 3 years is -$44.2 million, with a median of -$39.8 million recorded in 2024.
  • Peak annual rise in Free Cash Flow hit 47.65% in 2025, while the deepest fall reached 3.61% in 2025.
  • Over 3 years, Free Cash Flow stood at -$60.3 million in 2023, then grew by 27.42% to -$43.7 million in 2024, then skyrocketed by 31.13% to -$30.1 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$30.1 million, -$33.8 million, and -$30.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.